Infliximab biosimilar GP1111: a review of 5 years’ post-approval experience

Thomas W. J. Huizingaa Department of Rheumatology, Leiden University Medical Center, Leiden University, Leiden, The NetherlandsView further author information

Valeria Dipasqualeb Pediatric Gastroenterology and Cystic Fibrosis Unit, Department of Human Pathology in Adulthood and Childhood “G. Barresi”, “G. Martino” University Hospital, University of Messina, Messina, ItalyView further author information

Markus Zabranskyc Global Medical Affairs, Sandoz/HEXAL AG, Holzkirchen, GermanyCorrespondence[email protected]
View further author information

Jens Heynd Global Clinical Development, Sandoz/HEXAL AG, Holzkirchen, GermanyView further author information

Claudio Romanob Pediatric Gastroenterology and Cystic Fibrosis Unit, Department of Human Pathology in Adulthood and Childhood “G. Barresi”, “G. Martino” University Hospital, University of Messina, Messina, ItalyView further author information

Infliximab biosimilar GP1111: a review of 5 years’ post-approval experience

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Infliximab biosimilar GP1111: a review of 5 years’ post-approval experience

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date